Federal Research Institute of Pediatric Hematology, Oncology and Immunology Report issue

Government Phase 1 Phase 2 Phase 3
Founded: Moscow Russian Federation (1991)

Organization Overview

First Clinical Trial
2008
NCT01953770
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology | Federal Research Center for pediatric hematology, oncology and immunology | Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Aplastic (Phase 3)

beta-Thalassemia (Phase 3)

Communicable Diseases (Phase 3)

Deficiency Diseases (Phase 2)

Graft vs Host Disease (Phase 3)

Granuloma (Phase 2)

Granuloma, Plasma Cell (Phase 3)

Granulomatous Disease, Chronic (Phase 2)

Hematologic Diseases (Phase 3)

Hepatoblastoma (Phase 3)

Histiocytosis (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Hodgkin Disease (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Nijmegen Breakage Syndrome (Phase 2)

Opportunistic Infections (Phase 3)

Pancytopenia (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Sprains and Strains (Phase 2)

Syndrome (Phase 2)

Thalassemia (Phase 3)

Thrombocytopenia (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 37